3 results
To compare tumor [11C]erlotinib pharmacokinetics in NSCLC patients with and without erlotinib therapy. Also, to assess the relationship of venous sampling versus arterial, of tumor [11C]erlotinib uptake and blood flow with and without therapy, and…
Primary Objective:To determine whether the addition of eryaspase to chemotherapy improves overall survival (OS) in second-line treatment of pancreatic adenocarcinoma compared to chemotherapy alone.Secondary Objectives:• To compare progression-free…
To evaluate interlesional and intralesional differences in [11C]erlotinib uptake in EGFR mutated (EGFR+) NSCLC patients who are at different stages in their TKI treatment. To correlate tumor [11C]erlotinib uptake to EGFR mutational status, tumor…